新型细胞系面板揭示高级别浆液性卵巢癌铂类耐药的非遗传介导因素与表型多样性
研究以高级别浆液性卵巢癌为模型,建立5个体外和2个体内铂类耐药模型,经全基因组测序和RNASeq分析发现耐药细胞源自预先存在的祖先克隆,无统一突变原因,但顺铂和卡铂耐药细胞反复出现与细胞外基质相关的基因表达变化,且多数富集通路在两种耐药细胞中独特演化。
要点
- 铂类耐药细胞系源自预先存在的祖先克隆,未发现统一的突变原因。
- 顺铂和卡铂耐药细胞反复出现与肿瘤微环境特别是细胞外基质相关的基因表达变化。
- 多数显著富集的生物学通路在顺铂或卡铂耐药细胞系中独特演化,导致不同的腹腔内行为。
核心结论
- 临床相关且可用的模型揭示非遗传因素在化疗耐药演化中的关键作用。
- 耐药癌细胞在多种情境下反复表达与细胞外基质相关的生物学通路。
- 反复的基因表达变化可能提供铂类治疗期间的适应优势,且癌细胞内在机制影响肿瘤微环境。
- 所鉴定的候选基因和通路可能为铂类耐药高级别浆液性卵巢癌提供治疗机会。
研究设计与样本
- 研究建立五个体外和两个体内铂类耐药高级别浆液性卵巢癌模型,并通过全基因组测序、RNASeq和腹腔内模型创建对整个细胞面板进行表征。
主要发现
- 突变特征分析表明铂类耐药细胞系从预先存在的祖先克隆演化而来,但未发现统一的耐药突变原因。
- 顺铂耐药和卡铂耐药细胞演化的基因表达反复变化与多名复发高级别浆液性卵巢癌患者的独立样本显著重叠。
- 与肿瘤微环境特别是细胞外基质相关的基因本体生物学通路在顺铂耐药细胞、卡铂耐药细胞以及人类耐药/难治样本中反复富集。
- 多数显著过代表的基因本体生物学通路在顺铂或卡铂耐药细胞系中独特演化,导致反映人类复发高级别浆液性卵巢癌不同临床表现的多样腹腔内行为。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Resistance to cancer therapy is an enduring challenge and accurate and reliable preclinical models are lacking. We interrogated this unmet need using high grade serous ovarian cancer (HGSC) as a disease model. METHODS: We created five in vitro and two in vivo platinum-resistant HGSC models and characterised the entire cell panel via whole genome sequencing, RNASeq and creation of intraperitoneal models. RESULTS: Mutational signature analysis indicated that platinum-resistant cell lines evolved from a pre-existing ancestral clone but a unifying mutational cause for drug resistance was not identified. However, cisplatin-resistant and carboplatin-resistant cells evolved recurrent changes in gene expression that significantly overlapped with independent samples obtained from multiple patients with relapsed HGSC. Gene Ontology Biological Pathways (GOBP) related to the tumour microenvironment, particularly the extracellular matrix, were repeatedly enriched in cisplatin-resistant cells, carboplatin-resistant cells and also in human resistant/refractory samples. The majority of significantly over-represented GOBP however, evolved uniquely in either cisplatin- or carboplatin-resistant cell lines resulting in diverse intraperitoneal behaviours that reflect different clinical manifestations of relapsed human HGSC. CONCLUSIONS: Our clinically relevant and usable models reveal a key role for non-genetic factors in the evolution of chemotherapy resistance. Biological pathways relevant to the extracellular matrix were repeatedly expressed by resistant cancer cells in multiple settings. This suggests that recurrent gene expression changes provide a fitness advantage during platinum therapy and also that cancer cell-intrinsic mechanisms influence the tumour microenvironment during the evolution of drug resistance. Candidate genes and pathways identified here could reveal therapeutic opportunities in platinum-resistant HGSC.
引用
- Hoare JI, Hockings H, Saxena J, et al. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer. Gynecol Oncol. 2022. PMID: 35918200. doi:10.1016/j.ygyno.2022.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。